Sponsor

Tandem Diabetes Care, Inc.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Tandem Diabetes Care, Inc. appears in 48 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials48
Recruiting shown3
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

48 shown
The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in FranceNCT07211126 · lead sponsor · 2026-03-03
RECRUITING
Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 DiabetesNCT07325461 · lead sponsor · 2026-02-18
COMPLETED
Tandem Freedom - Feasibility Trial 2NCT06834568 · lead sponsor · 2025-03-24
COMPLETED
PS230005 Control-IQ 1.5 Post-Approval StudyNCT06717451 · lead sponsor · 2025-01-30
COMPLETED
Sigi Insulin Management System - A First-in-Human Study in Adults With Type 1 DiabetesNCT05973422 · lead sponsor · 2024-05-31
UNKNOWN
Tandem Freedom Feasibility Study 1NCT06428591 · lead sponsor · 2024-05-29
COMPLETED
Investigational Extended Wear Insulin Infusion Set in People With Type 1 DiabetesNCT06273124 · lead sponsor · 2024-03-07
COMPLETED
A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 DiabetesNCT05785832 · lead sponsor · 2023-06-01
COMPLETED
Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 DiabetesNCT05683392 · lead sponsor · 2023-02-01
COMPLETED
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 DiabetesNCT05403502 · lead sponsor · 2022-08-31
COMPLETED
Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)NCT05422053 · lead sponsor · 2022-06-29
COMPLETED
Adaptation of Insulin Delivery Settings to Improve Clinical Outcomes With AID UseNCT05204134 · lead sponsor · 2022-03-24
COMPLETED
Control-IQ Technology in Individuals With Type 2 DiabetesNCT05111301 · lead sponsor · 2021-11-30
COMPLETED
Control-IQ Technology 2.0 Adult and Adolescent Feasibility StudyNCT05014789 · lead sponsor · 2021-08-19
COMPLETED
Control-IQ Observational (CLIO) Post-Approval StudyNCT04503174 · lead sponsor · 2020-08-04
COMPLETED
Diabetes Pump With Predictive Low Glucose Suspend Pivotal TrialNCT03195140 · lead sponsor · 2017-08-11
COMPLETED
Tandem Predictive Low Glucose Suspend Inpatient Feasibility StudyNCT02877771 · lead sponsor · 2016-08-01
COMPLETED
Validation Study of G4 User InterfaceNCT01142895 · lead sponsor · 2010-05-01
COMPLETED
Insulin Delivery With Self-Adjusting Closed-Loop and Behavioral Glycemic Control Enhanced by PredictionNCT07507708 · collaborator · 2026-05-14
RECRUITING
Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin DeliveryNCT06880835 · collaborator · 2025-06-05
RECRUITING
Effectiveness of Artificial-Intelligence (AI) Bolus Priming Added to an Existing Fully Automated Control Algorithm (AIDANET)NCT07517770 · collaborator · 2026-05-01
NOT_YET_RECRUITING
A Randomized Parallel Clinical Trial of AIDANET, an Automated Insulin Delivery Algorithm, in Fully Closed-Loop Vs Hybrid Closed-Loop Mode In Adults With Type 1 Diabetes (AIDANET At Home)NCT07039617 · collaborator · 2025-09-02
ACTIVE_NOT_RECRUITING
AIDANET PediatricsNCT07020936 · collaborator · 2025-07-21
ACTIVE_NOT_RECRUITING
Safety and Feasibility Testing of a Smaller Network Version of AIDANETNCT06633965 · collaborator · 2024-11-20
COMPLETED
Adaptive Biobehavioral Control (ABC) in a Closed-Loop SystemNCT05610111 · collaborator · 2023-01-18
COMPLETED
Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 DiabetesNCT04614168 · collaborator · 2021-07-26
COMPLETED
Hybrid Closed Loop in High Risk Youth With Type 1 DiabetesNCT04807374 · collaborator · 2021-06-01
COMPLETED
The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 DiabetesNCT04796779 · collaborator · 2021-04-21
COMPLETED
Use of Closed Loop Insulin Delivery for Glucose Control in Patients With Insulin Dependent Diabetes Mellitus After Kidney TransplantationNCT04189510 · collaborator · 2021-04-01
WITHDRAWN
Assessing the Impact of Control-IQ TechnologyNCT04838561 · collaborator · 2021-03-15
COMPLETED
Artificial Pancreas - Adolescent Physiology & Psychology Longitudinal EvaluationNCT04510506 · collaborator · 2020-11-19
COMPLETED
Web-Based Simulation Tool For Self-Management Support In Type 1 Diabetes MellitusNCT04439903 · collaborator · 2020-10-12
COMPLETED
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)NCT04016662 · collaborator · 2020-09-28
COMPLETED
Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 DiabetesNCT04233034 · collaborator · 2020-07-09
COMPLETED
Efficacy of Closed-loop Insulin Therapy in Adults Prone to HypoglycemiaNCT04266379 · collaborator · 2020-05-13
UNKNOWN
SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes MellitusNCT04201496 · collaborator · 2020-02-24
COMPLETED
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6NCT04084171 · collaborator · 2019-09-26
COMPLETED
A Study of t:Slim X2 With Control-IQ TechnologyNCT03844789 · collaborator · 2019-06-06
COMPLETED
The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension)NCT03591354 · collaborator · 2019-01-17
COMPLETED
Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily InsulinNCT03804983 · collaborator · 2019-01-15
COMPLETED
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery SystemNCT03674281 · collaborator · 2018-09-24
COMPLETED
The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial PancreasNCT03563313 · collaborator · 2018-06-28
COMPLETED
Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski CampNCT03369067 · collaborator · 2017-12-18
COMPLETED
A Pilot Test of t:Slim X2 With Control-IQ TechnologyNCT03368937 · collaborator · 2017-12-08
COMPLETED
International Diabetes Closed Loop (iDCL) Trial: Research Site Training ProtocolNCT02844517 · collaborator · 2016-11-01
COMPLETED
Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop ControlNCT02679287 · collaborator · 2016-02-01
COMPLETED
Closed Loop Control in Adolescents Using Heart Rate as Exercise IndicatorNCT01945060 · collaborator · 2013-09-01
COMPLETED
Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes MellitusNCT01839370 · collaborator · 2013-07-01
COMPLETED

Drugs studied in this sponsor's trials

1 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Tandem Diabetes Care, Inc. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

placebo RxCUI 8375 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

collaborator30
lead sponsor18
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.